Medical Co.'s TULSA-PRO Installed Base Growth and CAPTAIN Trial Data Could Accelerate Adoption in 2026"
Research Report
Target Raised on CA Pharma Co. as EBITDA Margins Sustain Upward Trajectory
Research Report
Biotech With Groundbreaking Diabetes Treatment Secures CA$7.1M Breakthrough Financing
Record Profits, a Vape Market Landgrab, and a CA$250M Facility Bought for CA$27M
Research Report
Biotech Expands Financing to CA$2M as AI-Driven Cancer Drug Programs Advance
New Data, Analyst Calls, and Pipeline Milestones Put Spotlight on Next Wave of Weight-Loss Drug Developers
Biotech Company Advances Breakthrough Hyperinsulinism Treatment
CleanTech Company Advances FDA-Cleared Solution Toward Big Gains
Clean technology and life sciences company BioLargo Inc. (BLGO:OTCQX) announces that its subsidiary, Clyra Medical Technologies, Inc., has received its first commercial stocking order for ViaCLYR, its FDA-cleared wound irrigation solution. Read why one analyst believes the company has made significant progress in several initiatives.Technically Oversold with Support, Solid Patents, & A Heavyweight Board: Is This Stock Set to Soar?
Contributed Technical Analyst Opinion
Arch Biopartners Inc (ARCH:TSXV; ACHFF:OTCQB) is a therapeutic biotech company focused on developing novel, on-target drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The companys board and scientific advisory team of seasoned pros includes Dr. Patrick Vink (M.D., M.B.A.), Chairman of the Board, and Dr. Dan Muruve (M.D.), Chief Scientific Officer and internationally recognized nephrologist. The technical action on the charts suggests a significant surge in the stock price could be imminent. Experts Spotlight a Persistent Barrier in Advanced Cancer Therapies
Rakovina Therapeutics Inc. (RKV:TSX.V) outlined its AI-driven approach to brain-penetrant ATR and mTOR inhibitors during the 9th Annual DNA Damage Response Inhibitors Summit in Boston. The company also reported inbound interest in its kt-3000 series as potential payloads for antibody-drug conjugates.FDA Grants Orphan Drug Status to Experimental Melanoma Therapy After Phase 1 Results
TuHURA Biosciences Inc. (HURA:NASDAQ) said the FDA granted Orphan Drug Designation to IFx-2.0 for stage IIB to stage IV cutaneous melanoma. The designation was based on data from the companys previously completed Phase 1 clinical study.Drug Developer Uncovers Excellent Progress in 200-Patient ALS Study
Biopharmaceutical company MediciNova Inc. (MNOV:NASDAQ) announces that by the end of January, 12 sites in the U.S. have been activated and 100 patients have been enrolled in its studying evaluating its treatment for ALS. Read what one analyst says investors should be looking for from the company in the coming year.Biopharma Reaches 50% Enrollment in New ALS Drug Program
Research Report
MediciNova Inc. (MNOV:NASDAQ) enrolls 100 patients in the SEANOBI Expanded Access Program for MN-166 (ibudilast), noted a D. Boral Capital report. Read on to learn the many potential catalysts ahead for this California-based firm. 
Streetwise Key Charts
